These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24698227)

  • 1. Up-front combination therapy in pulmonary arterial hypertension: from clinical trials to 'real world' observational studies.
    Grignola JC
    Int J Cardiol; 2014 May; 173(3):349-50. PubMed ID: 24698227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic and pharmacokinetic rationale for combination therapy in pulmonary arterial hypertension.
    Gokhman R; Smithburger PL; Kane-Gill SL; Seybert AL
    J Cardiovasc Pharmacol; 2010 Dec; 56(6):686-95. PubMed ID: 20838230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
    Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
    Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
    Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
    Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension.
    O'Callaghan DS; Savale L; Jaïs X; Natali D; Montani D; Humbert M; Simonneau G; Sitbon O
    Respir Med; 2010 Jul; 104 Suppl 1():S74-80. PubMed ID: 20418081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.
    Tokunaga N; Ogawa A; Ito H; Matsubara H
    J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex multidrug therapy in a patient with pulmonary hypertension before and after orthotopic heart transplantation. A case report.
    D'Alto M; Alfano D; Maiello C; Sarubbi B; Santoro G; Argiento P; Galdieri N; Russo MG; Cotrufo M; Calabrò R
    J Cardiovasc Med (Hagerstown); 2007 Nov; 8(11):950-2. PubMed ID: 17906484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
    Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
    J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.